In today’s era of unprecedented opportunities and complexity within personalized medicine, it has become critical innovators in the space to adopt a collaborative approach with outside experts in order to quickly and affordably bring new products and services to market. And, as it turns out, collaboration may also be the key to achieving mainstream clinical adoption.

Hosted by Foley & Lardner LLP and the Personalized Medicine Coalition, the 4th Annual Business of Personalized Medicine Summit will examine in depth the financial-, regulatory-, policy-, R&D-, and technology-related complexities, trends, and opportunities impacting the marketplace and the future of health care by highlighting some of the innovative partnering and collaboration taking place throughout the industry. Join top executives from across multiple stakeholder perspectives to explore strategies for capitalizing on this challenging yet profitable market, plus solutions for advancing the field.

OPENING KEYNOTE

Margaret Anderson, Executive Director, FasterCures, a Center of the Milken Institute

Margaret Anderson is the executive director of FasterCures, a Washington DC-based center of the Milken Institute, which is driven by a singular goal – to save lives by speeding up and improving the medical research system. FasterCures focuses on spurring cross-sector collaboration, cultivating a culture of innovation and engaging patients as partners. Anderson is also acting president and CEO of the Melanoma Research Alliance, the largest private funder of melanoma research, and served as secretary of the board for years before taking on her recent leadership role. She is a founding board member and past-president of the Alliance for a Stronger FDA, is a member of the NIH National Center for Advancing Translational Sciences Advisory Council and Cures Acceleration Network Review Board, the National Health Council board, United for Medical Research Steering Committee, the Food and Drug Administration’s Science Board, Science Looking Forward Committee and the Institute of Medicine’s Forum on Drug Discovery, Development and Translation.

CLOSING KEYNOTE

Jonathan Hirsch, President & Founder, Syapse

Jonathan Hirsch is the Founder and President of Syapse, a software company transforming healthcare by bringing omics into routine medical use. At Syapse, Jonathan works closely with diagnostic and healthcare providers, helping translate customer problems into software solutions. Jonathan is an Advisory Board member of the SXSW Accelerator, a mentor for UCSF Lean Launchpad for Healthcare course, and a member of the Steering Committee of Free the Data!, an effort started by Genetic Alliance to crowdsource the interpretation of cancer genes.

FEATURED TOPICS

  • Understanding digital health solutions as personalized medicine products
  • Anatomy of a venture capital investment
  • Reimbursement trends and changes in payment policy
  • Models for data collection and sharing
  • Innovative next-generation sequencing technologies and applications
  • Regulation and use of biomarkers in drug discovery and clinical practice
  • Clinical adoption challenges and solutions from international pharma and provider perspectives

REGISTER TODAY

For a complete conference schedule, list of confirmed speakers, and registration details, visit www.personalizedmedicinesummit.com.

See you in September !